Condition
Circulating Tumor DNA (ctDNA)
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Unknown2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07310537Recruiting
Feasibility of Circulating Tumour DNA (ctDNA) Analysis Using Automated Capillary Blood Sampling
NCT05513144Unknown
Potential Clinical Utilities of Circulating Tumor DNA in Advanced HER2 Negative Gastric Cancer
NCT05027347UnknownPrimary
Detection of Plasma Circulating Tumor DNA in Gastric Cancer
Showing all 3 trials